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Abstract: Angiogenesis is one of the main processes that coordinate the biological events leading to a
successful pregnancy, and its imbalance characterizes several pregnancy-related diseases, including
preeclampsia. Intracellular interactions via extracellular vesicles (EVs) contribute to pregnancy’s
physiology and pathophysiology, and to the fetal–maternal interaction. The present review outlines
the implications of EV-mediated crosstalk in the angiogenic process in healthy pregnancy and its
dysregulation in preeclampsia. In particular, the effect of EVs derived from gestational tissues in pro
and anti-angiogenic processes in the physiological and pathological setting is described. Moreover,
the application of EVs from placental stem cells in the clinical setting is reported.
Keywords: extracellular vesicles; preeclampsia; angiogenesis
1. Introduction
Extracellular vesicles (EVs) have been established as a means of cellular communi-
cation and are involved in physiological and pathophysiological processes through the
transfer of bioactive molecules such as proteins, RNAs and lipids [1]. EVs are released by
all cell types and can be found in all body fluids. The subtype and composition of EVs
are dependent on the route of EV generation and parental origin, respectively [2]. The
content of EVs can be packaged based on signals received from other cells or environmen-
tal factors such as oxygen, glucose concentration and sheath stress. In pregnant women,
trophoblast-derived EVs are found in the blood [3], amniotic fluid [4], and urine [5]. These
EVs have placenta-specific markers such as HLA-G [6], syncytin-1 [7] and placental-type
alkaline phosphatase (PLAP-1) [8]. Due to their small size, EVs can cross the placental
barrier, thereby enabling feto–maternal communication throughout the pregnancy [9]
(Figure 1). Given that EVs are involved in a wide range of processes, it is no surprise
that they play an important role in pregnancy. EVs regulate various normal physiological
processes during pregnancy, including implantation of the embryo by regulation of the
endometrium, trophoblast invasion, immune regulation of maternal responses and spiral
artery remodeling [10]. Changes in the total number, content, and bioactivity of EVs have
been reported in pregnancy complications such as preeclampsia (PE) [11].
Angiogenesis, the process by which blood vessels form for the delivery of nutrients
to the body, is necessary both prior to and during pregnancy. A balance between pro and
anti-angiogenic factors during pregnancy is key to a successful pregnancy. Imbalance of
angiogenic factors, and subsequently, widespread endothelial dysfunction is considered
the hallmark of pregnancy-related diseases such as preeclampsia (PE) [12]. The clinical
manifestation of PE includes the development of hypertension after 20 weeks of gesta-
tion [13] and the coexistence of either proteinuria or other maternal organ dysfunction such
as renal insufficiency, liver dysfunction, neurological features including headache or visual
disturbances, hemolysis or thrombocytopenia, pulmonary edema [13–15]. Moreover, PE
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increases the risk of maternal and perinatal mortality and morbidity, and is associated with
future cardiovascular disease risk [16]. Preeclampsia is classified as a new onset hyper-
tensive pregnancy disorder. Depending on the time of delivery, early-onset preeclampsia
manifests before the 34th week of gestation and is described as a fetal disorder that is
associated with placental dysfunction and adverse fetal outcomes. Late-onset preeclampsia
requires delivery at or after the 34th week of gestation and is considered as a maternal
disorder associated with endothelial dysfunction and end organ damage [13].




Figure 1. Different EV subtypes released from the placenta during pregnancy. The main subtypes of extracellular vesicles 
reported include exosomes (30–150 nm) formed from intracellular endosomal compartments and characterized by expres-
sion of tetraspanins (CD63, CD81, CD9); microvesicles (100 nm–1 μm), which originate from cell plasma membrane, char-
acterized by CD 40; apoptotic bodies (>1 μm), which are released by apoptotic cells, express phosphatidylserine on their 
surface and caspase 3 and 7 internally. Due to their small size, EVs can cross the placental membrane and contribute to 
feto–maternal signaling. Placental EVs have been previously found in maternal circulation and shown to directly affect 
maternal endothelium. Created with BioRender.com (accessed on 18 May 2021). 
2. Pro-Angiogenic Functions of EVs in Healthy Pregnancy 
The influence of EVs on the angiogenic process has been reported in various in vitro 
and in vivo studies [12]. EVs are considered to modulate the angiogenic process through 
the transfer of several molecules including small RNA species and proteins. In particular, 
small RNA species, such as microRNA, are transferred by EVs and are considered pivotal 
for the reprogramming of target cells [35]. Lombardo et al. reported that miRNA-126 and 
p-STAT5 in endothelial-derived EVs are responsible for IL-3-mediated paracrine pro-an-
giogenic signals [36]. Similarly, endothelial-derived exosomes require miRNA-214 to sim-
ulate angiogenesis in recipient cells [37]. In vivo, injection of EPC-derived EVs containing 
the angiogenic miRNAs miRNA-126 and miRNA-296 in a mouse hind limb ligation model 
significantly increased capillary density and blood perfusion [38]. Several other mi-
croRNAs present in the EV cargo have been reported to be involved in the induction of 
angiogenesis, including miRNA-125a [39], miR31 [40] and miRNA-150 [41]. In parallel, 
several proteins released by EVs have also been found to be involved in the modulation 
of angiogenesis, including VEGF [42,43], FGF-2 [44], PDGF [43,45,46], c-kit [47], sphingo-
sine-1-phosphate [48], regulated on activation of normal T cell expression and secretion 
[48], CD40L [49], C-reactive protein [50–52], metalloproteases [49,53], stem cell factor [54], 
and urokinase-type plasminogen activator. Furthermore, EVs can promote angiogenesis 
through the transfer of key lipids and proteins involved in activation of PI3K [55], extra-
cellular signal-regulated kinase 1 and 2 [56–58], Wnt4/βcatenin [59], and nuclear factor-κB 
[60,61] pathways. 
In pregnancy, a large number of studies focus on the activity of EVs released by ma-
ternal and fetal cells, including endothelial cells, immune cells, trophoblast and stem cells 
with the latter being present in the umbilical cord, placenta, amniotic fluid and amniotic 
membranes (Figure 1). These EVs are capable of inducing tissue regeneration and angio-
genesis and can be found in maternal circulation starting from 7 weeks of gestation [62], 
in amniotic fluid [4], and urine [5]. The heterogeneity of EVs produced in this environment 
results in a plethora of pro-angiogenic factors being delivered to support the physiological 
development of normal pregnancy and the maintenance of endothelial homeostasis (Table 
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reported include exosomes (30–150 nm) formed from intracellular endosomal compartments and characterized by expression
of tetraspanins (CD63, CD81, CD9); microvesicles (100 nm–1 µm), which originate from cell plasma membrane, characterized
by CD 40; apoptotic bodies (>1 µm), which are released by apoptotic cells, express phosphatidylserine on their surface
and caspase 3 and 7 internally. Due to their small size, EVs can cross the placental membrane and contribute to feto–
aternal signaling. Placental EVs have been previously found in maternal circulation and shown to directly affect maternal
endothelium. Created with BioRender.com (accessed on 18 May 2021).
Despite great scientific advances, PE is still defined as a “disease of theories”. In-
sufficient placenta development including abnormal spiral artery remodeling, placental
hypoxia, oxidative stress, impaired angiogenesis and insufficient placental perfusion con-
tribute to the development of preeclampsia [17–19]. Over the last two decades, increasing
evidence suggests that angiogenic factors imbalance plays a pivotal role in PE pathogene-
sis [20,21]. Soluble fms-like tyrosine kinase 1 (sFlt-1), a soluble form of vascular endothelial
growth factor receptor 1 (VEGFR-1) extracellular ligand-binding domain, is the key anti-
angiogenic factor released by placenta during pregnancy. This soluble form of VEGFR-1
can bind to all isoforms of VEGF [22,23], as well as to the PlGF. Indeed, sFlt- 1 may act
as a decoy receptor and hinder VEGF signaling through binding to its cognate receptors,
thus inhibiting VEGF-mediated pro-angiogenic effects [24]. During normal pregnancy, the
levels of sFlt-1 increase throughout gestation, providing a limiting and protective barrier
for potentially unhealthy VEGF-dependent over signaling [25,26]. However, maternal
circulating sFlt-1 levels are significantly increased in PE compared to normal pregnancy
prior to the onset of the disease [27]. Furthermore, in vivo studies have showed that exoge-
nous administration of sFlt-1 led to typic l PE-like symptoms such a hyperten ion and
glomerular endotheliosis in regnant rats [20], whereas reduced circulating levels of free
sFlt-1 below critical threshold rescued the damaging effects of sFlt-1 [21,28–30]. Another
anti-angiogenic factor released by placenta is solub e endoglin (sEng), a soluble form of
the coreceptor of transforming growth factor-β (TGF-β), which acts as a decoy receptor
of TGF-β leading to a decrease in angiogenesis [31]. Not surprisingly, harmful molecules
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released from the placenta may reach the fetal circulation, causing endothelial dysfunction
in the fetus. Indeed, many reports [32,33] have described fetoplacental endothelial dys-
function associated with preeclamptic pregnancies (Figure 1). A vicious cycle is therefore
created, which is to the detriment of the mother and the fetus.
In pregnancy, EVs can stimulate or impede angiogenesis according to their content
and molecular expression, which in turn, is dependent on the cell of origin and on its
pathophysiological state. For instance, hypoxic conditions observed in the first trimester
of the pregnancy, modulate the release of EVs from cytotrophoblast and placental cells,
both in number and as cargo [34]. As the angiogenic aspects of EVs in pregnancy-related
diseases are relatively new, this review will present the current studies related to EVs and
their role in pregnancy and its associated complications.
2. Pro-Angiogenic Functions of EVs in Healthy Pregnancy
The influence of EVs on the angiogenic process has been reported in various in vitro
and in vivo studies [12]. EVs are considered to modulate the angiogenic process through
the transfer of several molecules including small RNA species and proteins. In particu-
lar, small RNA species, such as microRNA, are transferred by EVs and are considered
pivotal for the reprogramming of target cells [35]. Lombardo et al. reported that miRNA-
126 and p-STAT5 in endothelial-derived EVs are responsible for IL-3-mediated paracrine
pro-angiogenic signals [36]. Similarly, endothelial-derived exosomes require miRNA-214
to simulate angiogenesis in recipient cells [37]. In vivo, injection of EPC-derived EVs
containing the angiogenic miRNAs miRNA-126 and miRNA-296 in a mouse hind limb
ligation model significantly increased capillary density and blood perfusion [38]. Several
other microRNAs present in the EV cargo have been reported to be involved in the in-
duction of angiogenesis, including miRNA-125a [39], miR31 [40] and miRNA-150 [41].
In parallel, several proteins released by EVs have also been found to be involved in the
modulation of angiogenesis, including VEGF [42,43], FGF-2 [44], PDGF [43,45,46], c-kit [47],
sphingosine-1-phosphate [48], regulated on activation of normal T cell expression and
secretion [48], CD40L [49], C-reactive protein [50–52], metalloproteases [49,53], stem cell
factor [54], and urokinase-type plasminogen activator. Furthermore, EVs can promote
angiogenesis through the transfer of key lipids and proteins involved in activation of
PI3K [55], extracellular signal-regulated kinase 1 and 2 [56–58], Wnt4/βcatenin [59], and
nuclear factor-κB [60,61] pathways.
In pregnancy, a large number of studies focus on the activity of EVs released by
maternal and fetal cells, including endothelial cells, immune cells, trophoblast and stem
cells with the latter being present in the umbilical cord, placenta, amniotic fluid and
amniotic membranes (Figure 1). These EVs are capable of inducing tissue regeneration
and angiogenesis and can be found in maternal circulation starting from 7 weeks of
gestation [62], in amniotic fluid [4], and urine [5]. The heterogeneity of EVs produced
in this environment results in a plethora of pro-angiogenic factors being delivered to
support the physiological development of normal pregnancy and the maintenance of
endothelial homeostasis (Table 1). The following paragraphs will discuss the role of healthy
pregnancy-related EVs in angiogenesis, according to their different tissue types of origin.
2.1. Maternal Blood EVs during Pregnancy
The concentration and profile of placental EVs in normal pregnancies has been ex-
tensively studied. Salomon et al., demonstrated that the concentration of EVs in maternal
plasma increased more than two-fold towards the end of gestation [3]. The EVs in maternal
serum showed different functional properties at different gestation. The ability of EVs to
modulate endothelial cell migration decreased significantly over time, implying that EVs
are less bioactive as the pregnancy progresses. As the EVs profile and functional properties
may significantly change throughout gestation, it is important to study the different EVs
populations to fully understand their function. Moreover, while EVs prepared from either
maternal circulation or cord blood can enhance endothelial cell proliferation, migration,
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and promoted tube formation, the activity of EVs isolated from maternal serum is higher
than that of EVs from cord blood. This is likely due to the differential expressions of
microRNAs involved in regulating cell migration in maternal EVs and cord EVs, includ-
ing miRNA-210-3p, miR376c-3p, miRNA-151a-5p, miRNA-296-5p, miRNA-122-5p, and
miRNA-550a-5p [63].
2.2. Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs)-Derived EVs
UC-MSCs are a well-known source of EVs with pro-angiogenic activity. They are
involved in stimulating endothelial cell migration, proliferation, and angiogenesis in vitro
and activating the Wnt/β-catenin pathway [59]. Xiong et al. [64] characterized the
angiogenic content of UC-MSC-EVs, which were produced under hypoxic conditions,
in vitro [64]. They found that large number of pro-angiogenic factors, including VEGF,
VEGFR-2, MPC-1, angiogenin, tie-2/TEK and IGF were present in these EVs. Moreover,
UC-MSC-derived EVs from a healthy pregnancy in piglets showed upregulation of miRNA-
150, which was directly correlated with higher expression of VEGF and Notch1, underlining
exosome miRNA-150 as a major regulator of angiogenesis in utero [45].
2.3. Placental Explant EVs/Trophoblasts
EVs derived from placental tissue have been singled out for their tissue repair proper-
ties via angiogenesis regulation. The interest in placental derived-EVs offers us additional
information on the possible pathway those EVs can regulate during pregnancy. Salomon
et al. extracted EVs from placental MSCs and subjected them to in vitro and in vivo func-
tional assays [34]. The results showed an increase in endothelial cell migration and vascular
tube formation. In addition, Salomon et al. discovered multiple miRNAs enclosed in pla-
cental EVs, such as miR486-1-5p and miR486-2-5p, which target the pathways responsible
for migration, placental development, and angiogenesis [34]. Moreover, under hypoxic
conditions, the release of exosomes and the expression profile of pro-angiogenic factors
were increased, indicating that changes in oxygen tension during early pregnancy may
promote angiogenesis via release of placental MSCs-derived EVs [34]. EVs isolated from
trophoblasts were found to release EMMPRIN, which is a protein that contributes to spiral
artery remodeling [65]. EMMPRIN has been shown to promote both angiogenesis and
metalloproteinase gene expression in endothelial cells of the umbilical cord and to upreg-
ulate VEGF production though HIF1α expressing fibroblasts [65]. In addition, EVs from
trophoblast cells obtained via perfusion of placental explants were shown to contain en-
dothelial Nitric oxide synthase (eNOS) [66]. Indeed, EVs could transfer eNOS to endothelial
cells, resulting in vasodilation of the endothelium during normal pregnancies [65].
2.4. Amniotic Fluid Stem Cells EVs
Amniotic fluid stem cells (AFSC) have recently been of interest in regenerative
medicine. AFSCs express high levels of stem cell receptor factor, c-kit (CD117) and display
the characteristics of multipotent cells, and they can differentiate into all the germ cell layers
because of their fetal but non-embryonic origin [67]. The paracrine effect of these cells has
been attributed to signaling via EVs. AFSC-EVs contribute to multiple angiogenic processes
that aid in gestational development [68]. A substantial amount of evidence demonstrates
the pro-angiogenic, anti-apoptotic, and immunosuppressive effects of AFSC-EVs, both
in vitro and in vivo models of organ damage [69,70]. Sedrakyan et al. [71] used the high
expression of VEGFR1/2 on AFSC-EVs as an antagonist of VEGF-induced endothelial
damage in a murine model of Alport syndrome [71]. The excess of VEGF was bound to the
VEGFR receptors on the EVs, easing the symptoms of the disease.
2.5. Amnion EVs
The placenta is a complex organ responsible for most of the maternal and fetal health,
and as such is composed of both maternal and fetal tissue. The membrane of this fetal tissue
(amnion membrane) is comprised of cuboidal epithelial cells that stick to the basement
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membrane, and of an extracellular matrix with fibroblast-like cells. The 1 amnion epithelial
cells released by the amnion membrane are represented by epithelial characteristics and
membrane antigens. Administration of EVs released from these amnion epithelial cells
have been used as a therapy in different diseases such as idiopathic pulmonary fibrosis [72].
However, their potential for therapy in pregnancy-related diseases has been poorly ex-
plored. More research is needed to conclusively understand and explore the potential of
amnion EVs for therapy in pregnancy-related diseases [72].
Table 1. Angiogenic factors associated with EVs and their role in pregnancy.
Source Bio-Factor/Functional Assay Platform Reference
Umbilical cord blood miRNA-15, miRNA-150 In vitro Luo et al., 2018 [45]
Umbilical cord VEGF, VEGFR-2, MPC-1, angiogenin, tie-2/TEK and IGF In vitro (Xiong et al., 2018) [64]
Umbilical cord Activation of Wnt/β-catenin pathway In vitro (Zhang et al., 2015) [59]
Placental explant EVs Angiogenesis and migration In vitro and in vivo (Salomon et al., 2013) [34]
Trophoblast-EVs EMMPRIN In vitro and in vivo (Balbi et al., 2019) [69]
Maternal–blood EVs Shh In vivo (Martínez et al., 2006) [73]
Maternal–blood EVs enhances endothelial cell proliferation, migration, and tubeformation In vitro (Jia et al., 2018) [63]
Throphoblast-EVs eNOS In vitro (Motta-Mejia et al., 2017) [66]
Placental explants Flt/endoglin In vitro (D. Tannetta et al., 2014) [62]
3. Anti-Angiogenic Actions of EVs in Preeclampsia
As discussed above, placental-derived EVs play an important physiological role in
mother and fetus communication through the delivery of a range of proteins, lipids, and
nucleic acids [74]. On the other hand, alterations in the concentration and content of
placenta-derived EVs are associated with pregnancy-related diseases, such as PE [75–79].
Angiogenic imbalance is considered to be the main contributor of endothelial dysfunc-
tion, in PE [80]. Flt-1 and Eng have been detected on the surface of placental-derived
EVs [3,75,81]. These Flt-1 and Eng expressing EVs are capable of binding to pro-angiogenic
factors, VEGF, PlGF and TGF-β [75]. Interestingly, the capacity of Eng expressing placental-
EVs to bind TGF-βwas much higher in comparison to the affinity for VEGF and PlGF to
Flt-1 expressing EVs [76].
The anti-angiogenic effect of circulating EVs in PE appears to be, at least in part,
mediated by the presence of Flt-1 or Eng in the form of membrane receptors on the EV
surface, as these can act as decoy receptors by sequestering angiogenic soluble factors,
similarly to the presence of the soluble forms. Tannetta et al. [82] showed that EVs isolated
from preeclamptic placenta expressed higher level of Flt-1 in comparison to EVs isolated
from normal placenta. Application of EVs containing sFlt-1 to HUVEC cells led to a
reduction in tube formation, cell invasion and an increase in cellular permeability [82].
EVs isolated from first trimester placental explants treated with sera from either normal
pregnant women or preeclamptic women showed no significant differences in their size or
concentration. However, EVs isolated from preeclamptic sera-treated placental explants
were able to cause endothelial cell activation due to up-regulation of High Mobility Group
Box 1 (HMGB1) in EVs, a potent danger-associated molecular pattern/danger signal
that can lead to sterile inflammation [83]. Furthermore, administration of platelet or
endothelial cell-derived EVs to pregnant mice induced PE-like symptoms and decreased
embryonic vascularization [84]. Han et al. showed that infusion of EVs derived from
injured placenta rather than normal placenta led to the development of hypertension and
proteinuria in pregnant mice. These EVs released from injured placenta caused disruption
of endothelial integrity and enhanced vasoconstriction [85]. These studies highlighted a
possible pathogenic role of circulating EVs in PE. Studies in vivo have also confirmed the
role of EVs in affecting angiogenesis and inducing PE-like syndromes by administering
EVs derived from pre-eclamptic placentas in mice. The injection of those EVs resulted in
damage to the vasculature and poor fetal nutrition [81].
The shedding of EVs into the maternal blood in PE has also been shown to correlate
with systolic blood pressure [86]. Neprilysin (NEP), a membrane-bound metalloproteinase
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that is involved in vasodilator degradation, has been directly correlated with hypertension
(REF). Interestingly, NEP has been found on the surface of trophoblast-EVs. Moreover,
Gill et al. [87] showed that the level of NEP in the EVs derived from placenta and syncy-
tiotrophoblast cells were both augmented in preeclamptic women compared to normal
pregnant women, indicating that increased levels of NEP-expressing EVs in the mater-
nal circulation may play a role in causing PE-related symptoms including hypertension,
heart failure [87]. Furthermore, placental trophoblast-EVs in PE contain reduced levels
of endothelial nitric oxide synthase (eNOS), and thus reduced production of nitric oxide
production, a potent vasodilator (59), suggesting that PE-associated EVs may contribute to
decreased NO bioavailability, resulting in endothelial dysfunction. Additionally, EVs may
also inhibit angiogenesis by low-density lipoprotein receptor-mediated endocytosis [88],
and by CD36-dependent uptake of EVs and induction of oxidative stress [89,90].
Not surprisingly, the majority of studies that have investigated EV in the development
of PE have focused on the effect of placental EVs on the endothelium. Vascular smooth
muscle cells residing in vessels are also an important part of the processes that lead to
placentation and vascular remodeling. EVs from extravillous trophoblasts were reported
to promote vascular smooth muscle cell migration, thus suggesting their role in the remod-
eling of spiral arteries [91]. However, the possible contribution of EVs on vascular smooth
muscle cells in the pathophysiology of preeclampsia have not yet been researched.
Beside membrane-bound proteins, EVs derived from gestational tissues during com-
plicated pregnancies contain multiple miRNAs, which may play an anti-angiogenic role
under these conditions, particularly in PE [33]. Cronqvist et al. [92] demonstrated that
syncytiotrophoblast-derived EVs directly transferred functional placental miRNA that
directly targeted Flt-1 mRNA to primary human endothelial cells and subsequently reg-
ulated the expression of Flt-1, suggesting that miRNA enclosed in placental EVs may
directly affect the maternal and fetal endothelial function through regulating angiogenic
factors [92]. The miRNAs most commonly involved in angiogenic processes are outlined
below (Table 2) [11]. For example, miRNA-210, which has an anti-angiogenesis property is
actively secreted in placental-EVs. It has been found in the circulation of pregnant women
and the level of miRNA-210 was elevated in women with PE and hypoxia [93]. In addition,
EVs derived from trophoblast and endothelial cells contained miRNA-210 and its action
may be mediated through directly targeting ERK [43]. miRNA-520c-3p, another miRNA
found in trophoblast-EVs, can reduce invasiveness in cancerous cells [94,95]. Interestingly,
Takahashi et al. [95] showed that MiRNA-520c-3p was present in first-trimester trophoblast
cells and trophoblast cell lines and that overexpression of MiRNA-520c-3p in EVs signifi-
cantly inhibited cell invasion by targeting CD44. The results showed that EVs produced by
cells with miRNA-520c-3p overexpression significantly reduced invasiveness via repres-
sion of CD44. Moreover, several miRNAs which have been previously associated with
hypertension have been found to be differentially expressed in preeclamptic EVs, including
miRN26b-5p, miRNA-7-5p and miR181a-5p [96]. In addition, placental 19 miRNA cluster
(C19MC), a cluster almost exclusively expressed on the placenta [97], has been reported to
be altered in PE [94].
Altogether, the studies described above suggest that EVs derived from preeclamptic
placentas play a direct role in endothelial dysfunction and contribute to PE development
through their membrane-bound proteins and the release of internal molecules such as
anti-angiogenic proteins and miRNAs. However, recent studies have challenged these
theories. It has been shown that EVs isolated using the common methods may cause
contamination of soluble bioactive factors that may affect their resultant bioactivities [98].
O’Brien et al. [99] showed that placental explant-derived EVs had no significant effect on
angiogenesis in vitro when EVs were administered alone, in contrast with the effect of
EVs administered with conditioned medium. These data may suggest that the endothelial
dysfunction associated with PE is linked with the action of soluble factors rather than EVs.
To fully elucidate this point, future research on EVs bioactivity requires more stringent
design and planning. Moreover, EVs from different sources must be researched on different
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platforms (in vitro, in vivo, organ on a chip) and on different functional assays (invasion,
angiogenesis, apoptosis, etc.).
Table 2. Angiogenic factors associated with EVs and their role in pregnancy.




s-Eng in vitro and in vivo
(Chang et al., 2018) [100]
(Schuster et al., 2020) [80]
(D. S. Tannetta et al., 2013) [76]




s-Flt in vitro and in vivo
(Chang et al., 2018) [81]
(Schuster et al., 2020) [80]
(D. S. Tannetta et al., 2013) [75]
(Salomon et al., 2014) [3]
Trophoblast EVs NEP In vitro (Gill et al., 2019) [87]
Placental explants VEGFR1/Endoglin in vivo (Tannetta et al. 2013) [82]
Placental explants HMGB1 In vitro (Xiao et al.,2017) [83]
Placental explant miRNA-210 In vitro (Anton et al., 2013) [93]
Placental explant miRN26b-5p, miRNA-7-5p andmiR181a-5p In vitro (Zhang et al., 2020) [96]
Placental explant C19MC associated miRNA In vitro (Morelli et al., 2012) [94]
Maternal circulation miRNA-486-1-5p,miRNA-486-2-5p In vitro (Salomon et al., 2013) [34]
Trophoblast EVs miRNA-520c-3p In vitro (Takahashi et al., 2017) [95]
Serum derived EVs Syncitin-2 X (Vargas et al., 2014) [7]
4. Potential Clinical Applications of Pregnancy Related EVs in Therapy and
Diagnostic Applications
Stem cell from gestational tissues such as the umbilical cord, the placenta, fetal mem-
branes (amnion) and amniotic fluid appear to be a rich source of EVs with promising
therapeutic activity. The advantage of therapeutic use of EVs relies on the lack of replica-
tion and immunogenicity in respect to the parental cells. The administration process is
more straightforward than the one for cells, as they can be stored and generated with a
higher economic benefit. Furthermore, unlike stem cells, no cases of tumor-related down-
falls have been reported so far [101]. Placental tissue-derived EVs have been studied in
clinical trials since the 2000s [102]. Currently, most of these clinical trials of EVs-based
therapies are focused on conditions such as melanoma [103], cancers [104], type II diabetes
(NCT02138331) and cutaneous ulcers (NCT02565264), rather than pregnancy-related dis-
orders. Recently, the FDA approved a clinical trial using amniotic fluid-sourced acellular
components for COVID-19 treatment (NCT04384445). This treatment claims to contain nat-
urally occurring hyaluronic acid, proteins, and exosomes, administered intravenously with
1 mL, containing 2–5 × 1011 particles. However, the characterization of the amniotic fluid
vesicles was not provided [105]. Unfortunately, these studies only looked at small cohorts
of people. Nevertheless, these studies showed that using EVs as therapy could be a viable
option, although more studies are needed to conclusively understand the role of EVs and
how EVs exert their actions under different conditions [12]. The proper characterization of
cell-secretome other than EVs and the factors responsible for effects observed represent an
emerging issue in EV therapy.
Based on their origin and content, EVs can also be applied for diagnostic purposes.
The characteristics of EVs would make them the perfect candidate to act as a marker of
genetic disorders or early signs of pregnancy-related complications. For instance, the
levels of Syncytin-2, a protein specific to the placenta, has been shown to be significantly
reduced in serum-derived EVs from preeclamptic patients and could represent a potential
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biomarker to predict the development and severity of preeclampsia [7]. Miranda et al. [10]
previously used EV concentration and content to evaluate the stage of fetal development.
Considering these EVs can be extracted and analyzed directly from a maternal blood
sample, this presents an opportunity for the development of a non-invasive test in contrast
to the amniocentesis. This opportunity for a non-invasive test should be explored as it
would represent both a less invasive technique as well as a less risky method of analysis as
the risk to the fetus would be greatly diminished.
5. Conclusions
EVs are important cell-derived bio-factors involved in cell-to-cell communication,
and they are highly implicated in the physiological development of normal pregnancy
and in the maintenance of endothelial homeostasis. Multiple sources of angiogenesis-
related EVs are released from fetal tissues and are present in the maternal circulation. A
better characterization of their differential cargoes during pregnancy appears to be an
interesting field of research. Nevertheless, the pro-angiogenic and pro-regenerative EVs
from placental tissues can be further exploited in different clinical settings. In particular,
placental stem cell-derived EVs or amniotic fluid EVs are subject to increased interest
for organ regeneration and repair. Finally, knowledge of EV function and cargo might
be instrumental for the diagnosis and therapy of pregnancy-related disorders. Indeed, a
large number of studies indicate that placenta-released EVs show altered phenotype and
function. Placenta-derived EVs increase in maternal circulation in PE and when transferred
in murine experiments, can highly affect endothelium in synergy with soluble factors to
cause endothelial dysfunction.
However, knowledge of the involvement of EVs in placental angiogenic processes is
still limited, and more studies are still needed, especially on the early processes occurring
in the first trimester.
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